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THE NORDBADEN PROJECT FOR HEALTH CARE
UTILIZATION RESEARCH IN GERMANY
Schlander M, Schwarz O
Institute for Innovation & Valuation in Health Care (InnoVal-HC),
Eschborn, Germany
With a population of 82.5m, Germany represents the largest
health care market in Europe. Yet, research into epidemiology,
resource utilization, and actual cost associated with speciﬁc dis-
orders has been hampered by the fragmentation of the national
health care system. OBJECTIVES: 1) To establish an integrated
claims database in the German region of Nordbaden, allowing
retrospective patient-based analyses; 2) to evaluate how repre-
sentative the selected sample may be considered for Germany as
a whole; and 3) to assess its potential by determining adminis-
trative prevalence rates of ADHD. METHODS: The complete
claims database of the ofﬁcial physicians’ organization of Nord-
baden (KVNB) in South-Western Germany for the 4 quarters of
2003 was ﬁrst coded to protect the privacy of patients and physi-
cians, and subsequently integrated and restructured according to
patient pseudonyms, as to allow patient and disease speciﬁc
cross-sectional analyses. Sociodemographic and health care
related characteristics of the sample population were compared
with data for West Germany, East Germany, and Germany as a
whole. One-year prevalence rates were determined for attention-
deﬁcit/hyperactivity disorder (ADHD). RESULTS: Claims data
for 2.238m persons insured by the SHI (82.2% of the regional
population; cf. Germany: 70.4m or 85.3% SHI insured) were
available, representing—as judged by key sociodemographic and
medical indicators (which will be presented)—the German SHI
insured population. ADHD (hyperkinetic disorder: ICD-10,
F90.0, F90.1) prevalence rates were: age 0–6: 1.26% (boys:
1.72%, girls: 0.77%), age 7–12: 4.97% (boys: 7.15%, girls:
2.66%), age 13–19: 1.31% (males: 1.91%, females: 0.60%), and
adults: 0.04% (males: 0.04%, females: 0.03%). CONCLU-
SIONS: Especially when combined with data from regional hos-
pitals and sick funds, databases like the “Nordbaden Project”
will provide a valuable tool for studies of real-world health care
utilization and direct medical costs associated with deﬁned
medical conditions. Speciﬁc ﬁndings on ADHD will be discussed
in light of international epidemiological data.
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ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN
ADULTS: SF-6D UTILITIES FROM SF-36 SCORES IN A
RANDOMISED TRIAL OF ATOMOXETINE
Laing A,Aristides M
M-TAG, A division of IMS Health Economics and Outcomes
Research, London, London, UK
OBJECTIVES: To derive utilities for adults with ADHD from a
randomised trial of atomoxetine 40mg BID versus 80mg QD
(Adler et al., 2004). These patients are largely untreated and
there are few therapy alternatives. METHODS: Medical
Outcome Study Short Form-36 (SF-36) scores are converted into
a Quality Adjusted Life Year (QALY) value for key health states;
responder and non-responders without/with adverse event
(grouping deﬁned as per clinical trial). The method for conver-
sion is in accordance with that previously published (Brazier 
et al. 1998, 2004). A total of 218 clinical trial participants were
followed for 13 weeks. Pre-treatment utility data of all patients
is analysed to assess baseline utility values and is compared with
end of trial period. Missing data were addressed according to
ﬁve criteria. RESULTS: Mean and median results for utility
values for responder and non-responder groups produced 
consistent and sensible results (mean results presented unless
stated). Baseline utility was 0.634 and was consistent with non-
responder score at end of trial (0.630), as per expectation.
Responders had utility scores of 0.682 and 0.671, without/with
adverse events, respectively. All responders (i.e. regardless of
adverse event status) had a score of 0.678. The average gain in
utility at end of trial comparing non-responders with all respon-
ders was 0.048. Median results increased the utility gain to 0.08.
CONCLUSIONS: This analysis provided results that were ratio-
nal and consistent with efﬁcacy and safety ﬁndings with atom-
oxetine in the treatment of adults with ADHD. Improved utility
can be expected with treatment (0.048 to 0.08) and these data
can be used to populate an appropriate cost-utility analysis.
Conversion of SF-36 data to SF-6D values was informative and
consistent.
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DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF
QUETIAPINE IN COMBINATION THERAPY IN THE
MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER
Klok RM1,Al Hadithy AF1,Van Schayk NP2,Antonisse AJ2,
Brouwers JR1, Postma MJ1
1University of Groningen, Groningen, Groningen,The Netherlands;
2AstraZeneca BV, Zoetermeer, Zuid Holland,The Netherlands
OBJECTIVES: To estimate the cost-effectiveness of quetiapine in
combination therapy compared to current combination therapies
in the treatment of acute mania in bipolar I disorder using a dis-
crete event model. METHODS: A discrete event simulation
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model was used. In this model a cohort of 10.000 bipolar I dis-
order patients was created using Dutch data on relevant patient
characteristics. This cohort was then used for the comparison of
the different treatment options. The treatment options compared
in the model were: 1). quetiapine & lithium; 2). olanzapine &
lithium; and 3). risperidon & lithium. For effectiveness four trials
on quetiapine were used. The effect measure was the number of
serious side effects. Serious side effects were: extra pyramidal
symptoms and/or more than 7% weight gain. Included costs
were: drug costs, hospital costs, hospital visits and laboratory
tests (2003 price levels). RESULTS: For the combination therapy
of quetiapine & lithium, the incremental net costs per serious
side effect averted were €1203 compared to risperdon & lithium
and €3481 compared to olanzapine & lithium. The effectiveness
on hospital stay is comparable over the three combination ther-
apies compared. CONCLUSIONS: Serious side effects may be
averted with quetiapine & lithium therapy at incremental costs.
Whether these costs are acceptable requires further research into
the ‘willingness to pay’ to avert one serious side effect.
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GALANTAMINE REDUCES CAREGIVER BURDEN: RESULTS
FROM A NATURALISTIC STUDY
Nguyen E1, Camacho F2, Luong D1
1Janssen-Ortho Inc,Toronto, ON, Canada; 2Damos Inc,Toronto, ON,
Canada
OBJECTIVES: To quantify the effect of galantamine on burden
of caregivers of patients with Alzheimer’s Disease (AD) enrolled
in INSPIRE (Investigation in a Naturalistic Setting of Patients
Initiated on Reminyl). METHODS: INSPIRE is a prospective,
observational study conducted across Canada in general practice
and specialist sites, involving 471 patients 65 years or older with
mild to moderate AD. Patient and caregiver demographics were
recorded at baseline, with effectiveness measured by the Mini-
Mental State Examination (MMSE) and Physician’s Clinical
Global Impression—Disease Status (CGI) at both baseline visit
and ﬁnal visit at 3 months. Caregiver stress was assessed using
the Zarit Burden Interview (ZBI). Analysis was based on two-
sided paired t-test. RESULTS: This preliminary analysis included
248 patients and caregivers, all of whom had completed the
study at time of analysis. Of these patients, the mean age was
80.6 ± 6.5, 61% were female, 54% had a high school degree or
less, and 74% lived with their spouse or partner. The mean age
of caregivers was 61.4 ± 14.6. The caregiver sample was pre-
dominately female (75%), most lived with the patient (54%),
and 42% employed on a full-time or part-time basis. At base-
line, the mean caregiver ZBI score was 21.5 ± 12.6. Signiﬁcant
improvement in caregiver burden (mean change 1.5 ± 8.4, p =
0.006) was shown after three months of galantamine treatment.
CONCLUSIONS: The efﬁcacy and safety of galantamine has
been demonstrated in multiple randomized, double-blind,
placebo-controlled trials in patients with mild-to-moderate AD.
This naturalistic study shows that galantamine signiﬁcantly
reduces burden among caregivers of patients with AD. Overall,
galantamine has a broad ranging beneﬁcial effect from both
patient and caregiver perspectives.
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EFFECT OF BEHAVIOURAL AND PSYCHOLOGICAL
SYMPTOMS OF DEMENTIA (BPSD) ON COST OF CARE IN
THE CANADIAN OUTCOMES STUDY IN DEMENTIA
Herrmann N1, Lanctôt K1, Nguyen E2, Sambrook R3, Lesnikova N3
1University of Toronto and Sunnybrook & Women’s College Health
Sciences Centre,Toronto, ON, Canada; 2Janssen-Ortho Inc,Toronto,
ON, Canada; 3Syreon Corporation,Vancouver, BC, Canada
OBJECTIVES: To determine the contribution of behavioural
symptoms to the costs associated with caring for patients with
dementia. METHODS: Data from the Canadian Outcomes
Study in Dementia (COSID), a 3-year prospective study of com-
munity-dwelling dementia patients was examined. Cognition
was assessed with the Mini-Mental State Examination (MMSE)
and behaviour with the Neuropsychiatry Inventory (NPI).
Resource utilization was evaluated monthly with caregiver-
completed resource use (RU) questionnaires, which included fre-
quency of community resource use (e.g., home care nurses,
Meals-on-Wheels, etc.), hospitalization and respite care, outpa-
tient visits and drug use (direct costs), as well as questions about
time away from work or leisure activities for both patient and
caregiver (indirect costs). Costs were calculated in 2000 Cana-
dian dollars. RESULTS: Five hundred dementia patients and
their caregivers who provided a minimum of 6 of 12 completed
RU questionnaires were included in this 1-year preliminary
analysis. At baseline, average age of patients was 76.3 (±6.3),
47% were male, and 82% were diagnosed with AD. Average
MMSE was 22.4 (±4.5) and average NPI 8.8 (±11.1; range
0–69). Total costs were estimated at $1298 per month ($113 for
medication costs, $237 for other direct costs, and $948 for indi-
rect costs). An analysis of covariance model, that included NPI,
MMSE, gender, age, marital status, dementia diagnosis, type of
residence, region of Canada, and number of medical co-
morbidities, showed that greater cognitive impairment, i.e.,
lower MMSE (F = 12.77, p < 0.0004), female gender (F = 9.31,
p = 0.0024) and non-AD dementia diagnosis (F = 6.27, p =
0.0126) were signiﬁcant covariates. After accounting for the
covariates, there was a signiﬁcant association between cost and
NPI (F = 22.46, p < 0.0001). The incremental cost of a one-point
increase in NPI score was $32 per month (95% CI $18–$45).
CONCLUSIONS: Behavioural and psychological symptoms of
dementia (BPSD) contribute signiﬁcantly to the total costs of
caring for community dwelling dementia patients.
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HEALTH RELATED QUALITY OF LIFE (HRQOL) AND BURDEN
OF FAMILY CAREGIVERS OF DIALYSIS PATIENTS
Alvarez-Ude F1, Valdés C2, Rebollo P2, Estebanez C1
1Hospital General de Segovia. Instutute “Reina Sofía” for
Nephrological Research, Segovia, Segovia, Spain; 2Hospital
Universitario Central de Asturias and Institute Reina Soﬁa for
nephrological research, Oviedo, Asturias, Spain
OBJECTIVES: To evaluate the HRQoL and burden of family
caregivers of dialysis patients and to analyze which variables
were associated to it. METHODS: A sample of 221 patient-carer
pairs, stratiﬁed by age and gender, was randomly selected from
14 dialysis units: 152 patients were on hemodialysis and 69 on
peritoneal dialysis. Patients and carers answered the SF-36,
obtaining Physical (PCS) and a Mental (MCS) Component
Summary scores standardized by age and gender, and the Duke-
UNK Functional Social Support (FSS). Carers also answered the
Caregiver Burden Interview of Zarit (ZS). RESULTS: Mean PCS
and MCS scores of carers were 48.4 ± 13.8 and 48.0 ± 11.3
respectively. Multiple regression analysis showed that the vari-
ables associated to lower PCS of the carer were: higher ZS and
older patient age (R2 = 0.15; p < 0.001). Variables associated to
lower MCS were: higher ZS and lower FSS of the carer, and
lower MCS of the patient (R2 = 0.29; p < 0.001). Variables asso-
ciated to a higher ZS of carers were: lower FSS and lower PCS
and MCS scores of the carer and higher age and lower PCS and
MCS scores of the patient (R2 = 0.49; p < 0.001). Carers with
a MCS =< 42 points (cutoff point associated with depression)
were 28.3% (95%CI = 22.4–34.8). Logistic regression analysis
